FIA
LXEO icon

FNY Investment Advisers’s Lexeo Therapeutics LXEO Stock Holding History

FNY Investment Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,000
Closed -$20K – 1400
2025
Q2 		$20K Hold
5,000
– – 0.01% 554
2025
Q1 		$17K Buy
+5,000
New +$22.1K 0.01% 425

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Investment Advisers's LXEO Position: Q3 2025 in Review

FNY Investment Advisers sold out of Lexeo Therapeutics (LXEO) in Q3 2025, closing a stake of 5,000 shares — an estimated $20K sold.

FNY Investment Advisers first reported a position in LXEO in Q1 2025 and held it in 2 quarters. The position peaked at $20K in Q2 2025. 109 funds tracked by Wall St. Rank hold LXEO as of Q3 2025.

  • FNY Investment Advisers reported no remaining Lexeo Therapeutics position as of Q3 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 5,000 Lexeo Therapeutics shares in Q3 2025, an estimated $20K.
  • FNY Investment Advisers first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 2 quarters.
  • FNY Investment Advisers's Lexeo Therapeutics position peaked at $20K in Q2 2025.
  • 109 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2025.

Based on FNY Investment Advisers's 13F filing for Q3 2025, filed 15 Dec 2025.